Given the known increased risk of venous thromboembolism (VTE) associated with both oral contraceptive (OC) use and hormone replacement therapy (HRT), it is important to address questions about the prevention and management of hormone-associated VTE. Specifically, the objectives of this article are as follows: (1) to provide suggested clinical management approaches for the primary and secondary prevention of VTE for women with thrombophilia; (2) to provide suggested clinical management approaches for the primary and secondary prevention of VTE in the perioperative period for women taking OC or HRT; and (3) to provide practical management approaches for frequently encountered clinical scenarios relating to duration of treatment for hormone-associated VTE.
Anticoagulants Clinical Trials as Topic